TUMOR ABLATION TOOLS AND TECHNIQUES
    4.
    发明公开

    公开(公告)号:US20240206937A1

    公开(公告)日:2024-06-27

    申请号:US18288335

    申请日:2022-05-10

    申请人: SNIPE MEDICAL LTD

    发明人: Yuval TAFF Ben OMRI

    IPC分类号: A61B18/00

    摘要: An apparatus for use with a tumor comprises a tumor-ablating device that has a distal region that comprises (i) an inner shaft, comprising: (a) a first bioimpedance-sensing electrode, and (b) a first electroporation electrode, mounted at a fixed position proximally from the first bioimpedance-sensing electrode, and (ii) an outer shaft within which the inner shaft is coaxially disposed, the outer shaft comprising: (a) a second bioimpedance-sensing electrode, and (b) a second electroporation electrode, mounted at a fixed position distally from the second bioimpedance-sensing electrode. The inner shaft and the outer shaft are telescopically slidable with respect to each other in a manner that changes a first axial distance between the first electroporation electrode and the second electroporation electrode. Other embodiments are also described.

    System and method for pre-programmed cold atmospheric plasma

    公开(公告)号:US11737807B2

    公开(公告)日:2023-08-29

    申请号:US16774421

    申请日:2020-01-28

    发明人: Jerome Canady

    IPC分类号: A61B18/00 A61B18/04

    摘要: To determine appropriate treatment doses of cold atmospheric plasma (CAP), the Canady Helios Cold Plasma Scalpel was tested across numerous cancer cell types including renal adenocarcinoma, colorectal carcinoma, pancreatic adenocarcinoma, ovarian adenocarcinoma, and esophageal adenocarcinoma. Various CAP doses were tested consisting of both high (3 L/min) and low (1 L/min) helium flow rates, several power settings, and a range of treatment times up to 5 minutes. The impact of cold plasma on the reduction of viability was consistently dose dependent, however the anti-cancer capability varied significantly between cell lines. While the lowest effective dose varied from cell line to cell line, in each case an 80-99% reduction in viability was achievable 48 hours after CAP treatment. Therefore, it is critical to select the appropriate CAP dose necessary for treating a specific cancer cell type.